New Microfluidics Device Detects Cancer Cells in Blood
By LabMedica International staff writers Posted on 12 Mar 2019 |
Image: A diagram shows how the microfluidics device separates cancer cells from blood. The green circles represent cancer cells (Photo courtesy of Professor Ian Papautsky, PhD).
The ability to successfully isolate cancer cells is a crucial step in enabling liquid biopsy where cancer could be detected through a simple blood draw. This would eliminate the discomfort and cost of tissue biopsies, which use needles or surgical procedures as part of cancer diagnosis.
Liquid biopsy could also be useful in tracking the efficacy of chemotherapy over the course of time, and for detecting cancer in organs difficult to access through traditional biopsy techniques, including the brain and lungs. However, isolating circulating tumor cells from the blood is no easy task, since they are present in extremely small quantities.
Bioengineers collaborating with those at the University of Illinois Cancer Center (Chicago, IL, USA) have developed a device that can isolate individual cancer cells from patient blood samples. The microfluidic device works by separating the various cell types found in blood by their size. The device may one day enable rapid, cheap liquid biopsies to help detect cancer and develop targeted treatment plans.
The scientists 'spiked' 5 mL samples of healthy blood with 10 small-cell-lung cancer cells and then ran the blood through their device. They were able to recover 93% of the cancer cells using the microfluidic device. Previously developed microfluidics devices designed to separate circulating tumor cells from blood had recovery rates between 50% and 80%. When they ran eight samples of blood taken from patients diagnosed with non-small-cell lung cancer, they were able to separate cancer cells from six of the samples using the microfluidic device, while none for five healthy control subjects.
Ian Papautsky, PhD, a Professor of Bioengineering and senior author of the study, said, “Using size differences to separate cell types within a fluid is much easier than affinity separation which uses 'sticky' tags that capture the right cell type as it goes by. Affinity separation also requires a lot of advanced purification work which size separation techniques don't need. Without having to dilute, the time to run samples is shorter and so is preparation time.” They used whole blood in their experiments as well as blood diluted just three times, which is low compared to other protocols for cell separation using devices based on inertial migration. The study was published on February 25, 2019, in the journal Microsystems & Nanoengineering.
Related Links:
University of Illinois Cancer Center
Liquid biopsy could also be useful in tracking the efficacy of chemotherapy over the course of time, and for detecting cancer in organs difficult to access through traditional biopsy techniques, including the brain and lungs. However, isolating circulating tumor cells from the blood is no easy task, since they are present in extremely small quantities.
Bioengineers collaborating with those at the University of Illinois Cancer Center (Chicago, IL, USA) have developed a device that can isolate individual cancer cells from patient blood samples. The microfluidic device works by separating the various cell types found in blood by their size. The device may one day enable rapid, cheap liquid biopsies to help detect cancer and develop targeted treatment plans.
The scientists 'spiked' 5 mL samples of healthy blood with 10 small-cell-lung cancer cells and then ran the blood through their device. They were able to recover 93% of the cancer cells using the microfluidic device. Previously developed microfluidics devices designed to separate circulating tumor cells from blood had recovery rates between 50% and 80%. When they ran eight samples of blood taken from patients diagnosed with non-small-cell lung cancer, they were able to separate cancer cells from six of the samples using the microfluidic device, while none for five healthy control subjects.
Ian Papautsky, PhD, a Professor of Bioengineering and senior author of the study, said, “Using size differences to separate cell types within a fluid is much easier than affinity separation which uses 'sticky' tags that capture the right cell type as it goes by. Affinity separation also requires a lot of advanced purification work which size separation techniques don't need. Without having to dilute, the time to run samples is shorter and so is preparation time.” They used whole blood in their experiments as well as blood diluted just three times, which is low compared to other protocols for cell separation using devices based on inertial migration. The study was published on February 25, 2019, in the journal Microsystems & Nanoengineering.
Related Links:
University of Illinois Cancer Center
Latest Pathology News
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes